Human Papillomavirus Testing Market to Reach USD 3.7 Bn by 2035 - North America Leads, While Asia-Pacific Accelerates with Expanding Diagnostic Infrastructure

The global human papillomavirus testing market stands at the threshold of a decade-long expansion trajectory that promises to reshape diagnostic technology and cervical cancer screening solutions. According to the latest industry insights from Fact.MR, the market is projected to surge from USD 1.9 billion in 2025 to USD 3.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.9% during the forecast period.

This growth underscores the increasing emphasis on early detection, preventive diagnostics, and integration of molecular testing in women's healthcare. Rising awareness about HPV-related diseases, expanding government screening programs, and the adoption of next-generation diagnostic tools are key forces shaping the market's momentum across regions.

To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=9339

Evolving Role of Molecular Diagnostics in Cervical Cancer Prevention

HPV testing has emerged as a cornerstone of modern cervical cancer prevention strategies. Unlike traditional Pap tests, molecular HPV assays provide higher sensitivity in identifying high-risk strains associated with cervical cancer, offering earlier and more reliable detection.

By technology, PCR-based HPV tests continue to dominate the global landscape, holding an estimated 58% market share in 2025, driven by their precision, rapid turnaround, and expanding use in point-of-care settings. Hybrid Capture 2 (HC2) assays and next-generation sequencing (NGS)-based solutions are gaining traction for their multiplexing capabilities and broader genotype coverage, particularly in reference laboratories and research settings.

The shift toward co-testing (combining HPV testing with cytology) is reshaping clinical protocols, with many national screening programs now recommending HPV testing as the primary screening method for women aged 30 and above. This policy evolution has accelerated adoption in the United States, the United Kingdom, Australia, and several European and Asian healthcare systems.

Browse Full Report: https://www.factmr.com/report/human-papillomavirus-testing-market

Hospital and Diagnostic Laboratories Lead Test Volume

By end user, hospital-based laboratories and independent diagnostic labs collectively account for nearly 72% of total test volume in 2025. Their dominance stems from access to high-throughput instruments, trained personnel, and integration with electronic health record (EHR) systems that support large-scale population screening initiatives.

Meanwhile, point-of-care (POC) testing sites are emerging as a critical frontier for accessibility, particularly in low- and middle-income countries. Affordable, portable HPV test kits-supported by initiatives from organizations such as the WHO and GAVI-are expanding coverage in underserved areas across sub-Saharan Africa and Southeast Asia.

Regional Outlook: North America Retains Lead, APAC Gains Speed

North America remains the global leader in HPV testing adoption, valued at approximately USD 720 million in 2025 and projected to reach USD 1.3 billion by 2035, expanding at a CAGR of 6.1%. The United States, with robust insurance coverage and widespread inclusion of HPV tests in screening protocols, continues to drive the region's performance.

Europe follows closely, propelled by nationalized screening programs, strong public health infrastructure, and early transition toward molecular-based cervical screening. Countries like the UK, Germany, and Sweden are pioneers in the integration of HPV primary screening in public healthcare systems.

However, Asia-Pacific (APAC) is forecast to emerge as the fastest-growing region, advancing at a CAGR exceeding 7.8%. Rising awareness, improving healthcare access, and large-scale government initiatives in China, India, and Japan are creating fertile ground for expansion. Collaborations between diagnostic manufacturers and regional healthcare providers are further accelerating technology transfer and affordability in this segment.

Key Growth Drivers and Strategic Implications

The market's growth trajectory is underpinned by several structural and technological trends:

Government-led cervical cancer elimination programs emphasizing regular HPV testing as a first-line screening tool.
Integration of AI and automation in laboratory workflows, enhancing accuracy and reducing turnaround times.

Expansion of self-sampling HPV test kits, empowering women in remote regions to access preventive care.
Ongoing transition from cytology-based screening to HPV DNA-based diagnostics, improving sensitivity and long-term outcomes.

Increasing collaborations between diagnostic firms and public health agencies for awareness campaigns and affordable test distribution.

For diagnostic companies and healthcare providers, these factors highlight strategic opportunities to invest in digital pathology integration, diversify product portfolios, and leverage telemedicine networks for expanded reach.

Competitive Landscape: Innovation and Partnerships Define the Decade Ahead

The competitive environment remains dynamic, marked by continuous innovation in assay design, automation, and workflow integration. Leading players include:

Roche Diagnostics AG, Hologic Inc., QIAGEN N.V., Abbott Laboratories, Becton, Dickinson and Company (BD), Cepheid Inc., Thermo Fisher Scientific Inc., Seegene Inc., bioMérieux SA, Gen-Probe Inc., Luminex Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., BioCartis Group NV, and GeneFirst Ltd.

These companies are expanding their presence through strategic alliances with public health authorities, investments in automated testing platforms, and development of portable molecular systems aimed at improving accessibility in emerging markets.

Purchase Full Report for Detailed Insights

For access to full forecasts, regional breakouts, company share analysis, and emerging trend assessments, you can purchase the complete report here: https://www.factmr.com/checkout/9339

Looking Ahead: Toward a Preventive, Data-Driven Diagnostic Future

From its 2025 base of USD 1.9 billion, the HPV testing market is positioned for transformative growth through 2035, adding nearly USD 1.8 billion in incremental value. As molecular diagnostics converge with digital health solutions, the next decade will witness a shift toward preventive, data-driven, and decentralized screening ecosystems.

For investors, diagnostic companies, and policymakers, the focus will remain clear-scaling innovation, affordability, and access to HPV testing will be pivotal in achieving the WHO's 2030 cervical cancer elimination targets.

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@factmr.com

Check out More Related Studies Published by Fact.MR Research:

Trauma Fixation Device Market - https://www.factmr.com/report/trauma-fixation-device-market

Orthopedic Devices Market - https://www.factmr.com/report/4780/orthopaedic-devices-market

External Fixator Market - https://www.factmr.com/report/external-fixator-market

Trauma Devices Market - https://www.factmr.com/report/trauma-devices-market

Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.